Altimmune

Founding and History

Altimmune is a publicly traded company that has refocused its strategy around a single lead asset, pemvidutide. Over recent years, the company streamlined its pipeline to concentrate on metabolic and liver diseases, advancing pemvidutide through multiple mid-stage clinical studies and positioning the program for late-stage development.

Therapy Areas and Focus

Altimmune’s development efforts are concentrated on metabolic and liver-related diseases where weight loss and liver biology intersect. Current focus areas include metabolic dysfunction–associated steatohepatitis, obesity-linked cardiometabolic disease, alcohol use disorder, and alcohol-associated liver disease.

Technology Platforms and Modalities

Altimmune is developing peptide-based therapeutics, with pemvidutide designed as a dual agonist of the GLP-1 and glucagon receptors. The mechanism is intended to combine weight reduction with direct effects on liver metabolism and energy balance. The company’s strategy centers on evaluating this mechanism across multiple related indications rather than maintaining a broad discovery platform.

Key Personnel

Vipin Garg serves as Chief Executive Officer. The broader leadership team covers clinical development, regulatory affairs, finance, and operations, supporting execution across multiple mid-stage clinical programs.

Strategic Partnerships

Altimmune’s current strategy is primarily internally driven, supported by contract research, manufacturing, and clinical partners. Formal collaborations are disclosed selectively and are not central to the company’s operating model.

FAQ Section

What is Altimmune’s core science and biotech platform?
Altimmune’s development platform is built around pemvidutide, a dual GLP-1 and glucagon receptor agonist designed to address metabolic and liver disease through combined weight loss and liver-directed mechanisms.

What diseases and therapeutic areas does Altimmune focus on?
The company focuses on metabolic and liver diseases, including metabolic dysfunction–associated steatohepatitis, obesity-related cardiometabolic disease, alcohol use disorder, and alcohol-associated liver disease.

What programs and products are in Altimmune’s clinical pipeline?
Altimmune’s pipeline is centered on pemvidutide. The program has completed Phase II obesity studies, reported Phase IIb data in metabolic dysfunction–associated steatohepatitis, and is being evaluated in Phase II studies in alcohol use disorder, with additional development planned in alcohol-associated liver disease.

What is the latest company news and recent Altimmune events?
In 2025, Altimmune reported both 24-week and 48-week topline results from its Phase IIb IMPACT study in metabolic dysfunction–associated steatohepatitis. These data informed the company’s plans for end-of-Phase II regulatory discussions and preparation for late-stage development.

What clinical trial data and results has Altimmune announced?
Altimmune has disclosed multiple mid-stage clinical readouts for pemvidutide, including Phase II obesity data and Phase IIb liver histology data in metabolic dysfunction–associated steatohepatitis, alongside ongoing Phase II evaluation in alcohol use disorder.

What are Altimmune’s regulatory interactions and upcoming milestones?
Following completion of Phase IIb studies in metabolic dysfunction–associated steatohepatitis, Altimmune is preparing for regulatory discussions to define Phase III development. The company is also continuing Phase II execution in alcohol use disorder and advancing plans in alcohol-associated liver disease.

Who comprises Altimmune’s leadership team and what is their track record?
Altimmune is led by an executive team with experience in metabolic and liver disease development, regulatory engagement, and clinical execution. Current leadership has overseen the company’s transition to a focused, late clinical-stage strategy centered on pemvidutide.